Linvoseltamab recommended for eu approval by the chmp to treat relapsed/refractory multiple myeloma

Tarrytown, n.y., feb. 28, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (r/r) multiple myeloma (mm). the recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-cd38 monoclonal antibody, and have demonstrated disease progression on the last therapy. the european commission is expected to announce a final decision in the coming months.
REGN Ratings Summary
REGN Quant Ranking